key: cord-0997224-p8pyso49 authors: Huang, Jiao-Feng; Wang, Xiao-Bo; Zheng, Kenneth I.; Liu, Wen-Yue; Chen, Jun-Jie; George, Jacob; Zheng, Ming-Hua title: Obesity hypoventilation syndrome and severe COVID-19 date: 2020-07-31 journal: Metabolism DOI: 10.1016/j.metabol.2020.154249 sha: 50c60d61d89a15a1ce10bd65d6ec1e30e87661be doc_id: 997224 cord_uid: p8pyso49 nan Obesity hypoventilation syndrome and severe COVID-19 The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic by the World Health Organization [1] . Obesity is a common cause to aggravate the severity of respiratory diseases [2] which may place obese patients infected by SARS-CoV-2 at risk for pulmonary complications. We here report the case of a 23-year-old man who attended Wenzhou Central Hospital, Wenzhou, China (on January 21, 2020) after five days of fever, chills, headache, nasal congestion, cough and mild dyspnoea. Other medical comorbidities included metabolic associated fatty liver disease (MAFLD) [3] for five years, obstructive sleep apnoea hypopnea syndrome (OSAHS) for two years, and gout for one year, the latter treated with oral benzbromarone and bicarbonate. At the time of hospital admission, the most relevant clinical findings at baseline included a body mass index (BMI) of 37.3 kg/m 2 and body temperature of 39.4°C, white blood cell (WBC) count of 4.8 × 10 9 /L, neutrophil count of 3.1 × 10 9 /L, lymphocyte count of 1.2 × 10 9 /L, platelet count of 217 × 10 9 /L, C-reactive protein (CRP) of 37.8 mg/L, fasting blood glucose of 4.9 mmol/L, total cholesterol of 4.38 mmol/L, high-density lipoprotein of 0.62 mmol/L, low-density lipoprotein of 1.62 mmol/L, lactic acid dehydrogenase of 271 U/L, uric acid of 602 μmol/L, ferritin of 796 μg/L, lactate of 2.2 mmol/L, and PaO 2 /FiO 2 of 205 mm Hg. His chest computed tomography (CT) scan showed bilateral ground-glass opacities (Fig. 1A) . On the suspicion of COVID-19, the attending physician ordered salivary testing which was positive for SARS-CoV-2 by real-time RT-PCR assay (RT-PCR). The patient was immediately transferred to the isolation ward and commenced on nebulized α-interferon (5,000,000 IU) twice per day, oral lopinavir/ritonavir (200 mg/50 mg) twice per day, and oral arbidol (200 mg) thrice per day as recommended by the Chinese COVID-19 Interim Management Guidance (3rd edition) [4] . Because of the increased serum CRP, the patient was suspected to have a bacterial co-infection and empirical treatment with intravenous amoxicillin sodium and clavulanate potassium (1.2 g) thrice per day was commenced. Given his worsening dyspnoea and continued PaO 2 /FiO 2 of b300 mm Hg, the patient was subsequently given continuous high-flow oxygen inhalation (6 L/min) via a nasal catheter. Of note, the dyspnoea improved with arterial PaO 2 fluctuating between 94·5-127.5 mm Hg, while the arterial PaCO 2 remained high (46.8-53.9 mm Hg). Several attempts over the next 72 h to improve the PaCO 2 levels by lowering the oxygen therapy flow rate were to no avail. On day nine, the patient had significant improvement in symptoms with PaCO 2 b 40 mm Hg. A follow-up chest CT scan showed marked improvement in pulmonary infiltration (Fig. 1B) . Subsequently, a follow-up CT of the chest on day twenty-one showed evidence of further improvement (Fig. 1C) and he was discharged after two negative oropharyngeal swab tests and one faecal nuclei acid test for the virus by RT-PCR. On follow-up two weeks after discharge, his chest CT showed resolution of the pulmonary infiltrates (Fig. 1D) . This patient was diagnosed with type II acute respiratory failure as the likely result of COVID-19 in the context of other comorbidities including obesity and MAFLD. This is an interesting case in that up to now, only type I acute respiratory failure has been reported in severe COVID-19 patients [5] . Our patient's PaCO 2 levels remained elevated despite multiple attempts to adjust his oxygenation therapy. Fortunately, his hypercapnia improved on day nine which we believe was due to the improvement in pulmonary infiltrates. Previous studies have shown that obesity may cause restrictive lung disease with reduced vital capacity [6] . In our patient, obese hypoventilation syndrome (i.e. BMI ≥ 30 kg/m 2 and PaCO 2 N 45 mm Hg) was observed, possibly the result of combined severe pulmonary viral and bacterial infection; this can progress to malignant hypoventilation syndrome, a condition typically characterized by a poor prognosis [6] . The current practice guidance for treatment of COVID-19 suggests non-invasive oxygenation management targeting dyspnoeic individuals with PaO 2 /FiO 2 levels below 300 mm Hg or primarily in those with type I acute respiratory failure. However, no strategies exist for managing COVID-19 patients with obesity, chronic obstructive pulmonary disease or other diseases that may cause type II acute respiratory failure. In this patient, worsening hypercapnia might have led to serious sequelae if he had not recovered from his illness. Potential management strategies in deteriorating patients include the use of different oxygenation therapies. In high-flow oxygenation therapy, a moisturized and temperature-controlled airflow provides appropriate respiratory support with moderate positive airway pressure and helps remove mucus plugs to facilitate better oxygen exchange in the lungs and, thereby, increasing PaO 2 /FiO 2 . However, its effect on improving simultaneous hypercapnia is uncertain. Alternatively, non-invasive ventilation with an oxygen mask might significantly improve both hypoxemia and hypercapnia, in addition to managing the OSAHS. However, non-invasive ventilation is often uncomfortable and is associated with non-compliance and increases the risk of mucus plug accumulation in the lungs. Invasive ventilation may be the most effective strategy for these patient in that all the abovementioned complications can be appropriately managed, especially when the arterial blood gas pH is b7.3 (or correspondingly increased PaCO 2 levels). However, the risk that needs to be balanced is of nosocomial infection through prolonged intubation and transmission risk to healthcare providers of SARS-CoV-2. Overall, in obese patients combined with SARS-CoV-2 infection, especially in slow to recover patients, early invasive ventilation therapy might be a more appropriate strategy for managing a rapidly deteriorating pulmonary function. That said, it is reasonable to speculate that obesity with coexisting COVID-19 may predispose patients to the risk of more severe conditions such as obese hypoventilation syndrome. This is more likely in those that are older and with multiple comorbid diseases such as MAFLD, dyslipidaemia and OSAHS, and therefore less likely to be have adequate compensatory organ capacity. Future studies are needed to confirm these observations and to better understand the underlying mechanisms linking SARS-CoV-2 infection with the occurrence of type II acute respiratory failure in obese patients. The authors have no conflicts of interest related to this article. World Health Organization. WHO characterizes COVID-19 as a pandemic Obesity is a risk factor for greater COVID-19 severity A new definition for metabolic associated fatty liver disease: an international expert consensus statement Diagnosis and treatment of COVID-19 in China Clinical Characteristics of Coronavirus Disease 2019 in China Characteristics of patients with the "malignant obesity hypoventilation syndrome" admitted to an ICU None.